Neal Shore, MD, FACS, discussed findings from the SunRISe-4 trial of TAR-200 and cetrelimab in muscle-invasive bladder cancer ...

There is a high unmet need for effective neoadjuvant treatments for muscle-invasive bladder cancer for patients who cannot tolerate or refuse cisplatin chemotherapy.

A phase 3 trial of Johnson & Johnson's TAR-200 therapy in bladder cancer has failed to show efficacy, although the company is still confident in the potential of the programme. The SunRISe-2 study ...

Johnson & Johnson has kicked off a marketing application in the US for TAR-200 as a treatment for a form of bladder cancer, using a novel technology that releases the drug intravesically, or ...

SunRISe-4 evaluates TAR-200 and cetrelimab in muscle-invasive bladder cancer patients ineligible for cisplatin-based chemotherapy, showing promising pathological response rates. Adverse events were ...

Trinity Bivalacqua presented updated results from the BOND-003 cohort C study at EAU 2025, evaluating the efficacy and safety of intravesical cretostimogene grenadenorepvec in high-risk ...

In March 2025, Merck Sharp & Dohme LLC announced a study are to learn if people who receive V940 and pembrolizumab are alive ...

Leveraging the power of AI and machine learning technologies, researchers developed a more effective model for predicting how patients with muscle-invasive bladder cancer will respond to chemotherapy.

Tests to check for bladder cancer include physical exams, urine tests, and imaging. Biopsy or cystoscopy may help confirm a diagnosis. If you’re at high risk, at-home tests might help you screen ...

They say that maintaining a healthy diet, getting lots of sleep and practicing breathing exercises can all make giving birth go a little smoother. And while that may be good advice, Alissa Mosca ...

Dublin, March 27, 2025 (GLOBE NEWSWIRE) -- The "Anti-Neoplastic Agents Market Report 2025" has been added to ResearchAndMarkets.com's offering. This report covers market characteristics, size and ...